Parasite | Eso | Sto | Cancer | ESD
[Dr. Sinn's LiverTODAY 014 - Fibrinogen Á¤¸» Áß¿äÇÑ°¡?]
Fibrinogen Á¤¸» Áß¿äÇÑ°¡?
LiverTODYA 003¿¡¼ °£°æº¯ ȯÀÚÀÇ ÃâÇ÷ À§Çè ÀÎÀÚ¸¦ º¸°íÇÑ ³í¹®À» ¼Ò°³ÇÑ ¹Ù ÀÖ½À´Ï´Ù. ±× ³í¹®¿¡¼ Èï¹Ì·Ó°Ôµµ fibrinogenÀÌ Áß¿ä ÃâÇ÷ À§Çè ÀÎÀÚ¿´½À´Ï´Ù.
ÃÖ±Ù fibrinogenÀÌ Áß¿äÇÑ ¿¹Ãø ÀÎÀÚ¶ó´ÂÃß°¡ º¸°í°¡ Accepted article·Î ³ª¿Ô½À´Ï´Ù (Desborough. Hepatology 2016).
1,313¸íÀÇ ÀÔ¿øÇÑ °£°æº¯ ȯÀÚµéÀ» ºÐ¼®ÇØ º¸´Ï, 192¸íÀÌ ÃâÇ÷·Î ÀÔ¿øÇÏ¿´°í, 28ÀÏ »ç¸Á·üÀº 10%¿´½À´Ï´Ù. 1,313¸í ȯÀÚÁß fibrinogen levelsÀÌ Æò°¡µÈ 551¸í(42%)À» ºÐ¼®ÇÏ¿´´õ´Ï, fibrinogenÀÌ »ç¸ÁÀÇ À¯ÀÇÇÑ À§ÇèÀÎÀÚ¿´½À´Ï´Ù. ³óµµ°¡ 1g/L °¨¼ÒÇÒ ¶§¸¶´Ù »ç¸Á À§Çèºñ°¡ 29%¾¿ Áõ°¡ÇÏ¿´½À´Ï´Ù. ÀúÀÚµéÀº "It is unclear if hypofibrinogenemia reflects severity of underlying liver disease, or if it is a modifiable risk factor after bleeding that could be treated with fibrinogen supplementation."¶ó°í ¾ð±ÞÇÏ¿´½À´Ï´Ù.
FibrinogenÀº ½±°Ô Àê ¼ö ÀÖ½À´Ï´Ù. Varix bleeding µî GI bleeding ½Ã °£°æº¯ ȯÀڵ鿡¼ fibrinogenÀ» targetÀ¸·Î supplementation ÇÏ´Â °Í°ú PT INRÀ» targetÀ¸·Î FFP transfusion ÇÏ´Â °Í Áß ¾î¶² °ÍÀÌ ´õ ÁÁÀ»Áö Á¤¸» ±Ã±ÝÇÕ´Ï´Ù. ȯÀڵ鿡°Ôµµ Áß¿äÇÑ ¹®Á¦ÀÏ °Í °°½À´Ï´Ù.
[2016-12-1. ¾Öµ¶ÀÚ Áú¹®]
FibrinogenÀ» supplement ÇØ º» ÀûÀÌ ¾ø´Âµ¥... ¾î¶»°Ô ÇÏ´Â °ÍÀÎÁö¿ä?
[2016-12-1. ½Åµ¿Çö ±³¼ö´Ô ´äº¯]
Àúµµ Àß ÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. Fibrinogen ¼öÇ÷Àº FFP¿Í, cryoprecipitate¿Í fibrinogen concentrate¸¦ »ç¿ëÇÒ ¼ö Àִµ¥, FFP ´ë½Å (fibriongen¾çÀÌ Àû¾î¼), cryoprecipitate µîÀ» »ç¿ëÇØ º¼ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù.
* Âü°íÀÚ·á: Fibrinogen replacement therapy: a critical review of the literature. Franchini. Blood Transfus 2012
Fibrinogen replacement therapy is currently indicated as prophylaxis and therapy of haemorrhage in congenital and acquired fibrinogen deficiency, this latter being associated with liver failure, disseminated intravascular coagulation, massive transfusion and cardiac surgery)2,3. Hypofibrinogenaemia is defined by a decreased level of normal fibrinogen between 0.5 g/L and the lower limit of the normal range for the local laboratory (usually 1.5 g/L)4. Fibrinogen supplementation can be provided by transfusion of fresh-frozen plasma (FFP), cryoprecipitate and fibrinogen concentrate5,6. However, as FFP has several limitations including a low fibrinogen content, which means that large volumes must be given, and the risk of transfusion-related complications (e.g., transfusion-related acute lung injury [TRALI] and viral transmission), this critical analysis is focused on the role of cryoprecipitate and fibrinogen concentrate.
1) EsoTODAY - Esophageal diseases
2) SmallTODAY - Small bowel diseases
3) ColonTODAY - Colorectal diseases
4) Dr. Sinn's LiverTODAY - Liver diseases
© ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¼Òȱ⳻°ú ½Åµ¿Çö (2016-11-30)